Patrice Chevallier

Prof. Patrice Chevallier

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PCPatrice Chevallier
Patrice Chevallier
MMMohamad Mohty
Mohamad Mohty
BLBruno Lioure
Bruno Lioure
GMGerard Michel
Gerard Michel
NCNathalie Contentin
Nathalie Contentin
JHJean-Luc Harousseau
Jean-Luc Harousseau
Purpose: This retrospective multicenter study assessed the outcome of 51 patients with myeloid sarcoma (MS) who underwent allogeneic hematopoietic stem-cell transplantation (alloHSCT). Patients and Methods: Most patients had MS presenting in conjunction with acute myeloid leukemia (AML) or after AML. Six patients had isolated MS. The median time between diagnosis and alloHSCT was 8 months (range, 2.8 to 67). Forty patients were in complete remission (CR) at time of alloHSCT. Results: With a median follow-up of 33 (range, 1 to 182) months, the Kaplan-Meier estimates of overall survival (OS) and disease-free survival were 47% (95% CI, 33% to 61%) and 36% (95% CI, 24% to 50%) at 5 years. Twenty patients (39%) relapsed at a median of 204 (range, 35 to 1151) days after alloHSCT, with relapse being the major cause of death. In a Cox multivariate analysis, age ≥ 15 years and remission status at time of alloHSCT (CR v other) were associated with improved OS (hazard ratio [HR], 0.27; 95% CI, 0.12 to 0.65; P = .003; and HR, 0.22; 95% CI, 0.08 to 0.57; P = .002, respectively). Conclusion: We conclude that first-line alloHSCT performed early in the course of MS is a valid therapeutic option.

23 November 2009 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
PCPatrice Chevallier
Patrice Chevallier
IHI Hebia-Fellah
I Hebia-Fellah
LPL Planche
L Planche
TGT Guillaume
T Guillaume
CBC Bressolette-Bodin
C Bressolette-Bodin
BIB-M Imbert-Marcille
B-M Imbert-Marcille

10 November 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PCPatrice Chevallier
Patrice Chevallier
JDJacques Delaunay
Jacques Delaunay
PTPascal Turlure
Pascal Turlure
APArnaud Pigneux
Arnaud Pigneux
MHMathilde Hunault
Mathilde Hunault
JHJean-Luc Harousseau
Jean-Luc Harousseau
Purpose: To determine the antitumor activity and safety of a combination of gemtuzumab ozogamicin (GO), intermediate-dose cytarabine, and mitoxantrone (MIDAM) in patients with refractory or relapsed CD33+ acute myeloid leukemia (AML). Patients and Methods: We treated 62 patients with refractory (n = 18) or relapsed (n = 44) CD33+ AML. Median age was 55.5 years. Salvage regimen consisted of GO 9 mg/m2 on day 4, cytarabine 1 g/m2 every 12 hours on days 1 through 5, and mitoxantrone 12 mg/m2/d on days 1 through 3. Median follow-up time was 26.5 months. Results: Thirty-one patients (50%) achieved complete remission (CR), and eight patients (13%) had CR with delayed platelet recovery (CRp); the overall response (OR; CR + CRp) rate was 63%. A significantly higher OR rate was achieved in patients who had relapsed versus refractory AML (73% v 39%, respectively; P = .007) and patients with CD33 expression more than 98% of the blast population versus less than 98% (79% v 52.3%, respectively; P = .03). The overall, event-free, and disease-free survival rates were 41%, 33%, and 53% at 2 years, respectively. Leukocytosis more than 20,000/μL at MIDAM therapy, high-risk cytogenetics, and absence of postremission therapy were adverse prognostic factors. Age, disease status, and/or CD33 expression did not influence survival parameters. Four early toxic deaths occurred; a grade 3 to 4 hyperbilirubinemia rate of 16% was observed, and two patients had veno-occlusive disease (3%). Conclusion: The MIDAM regimen seems to be an effective salvage regimen for refractory/relapsed CD33+ AML patients. These encouraging results support the need for a randomized phase III trial before considering this combination of GO and chemotherapy as superior or the standard of care treatment for refractory/relapsed CD33+ AML patients.

17 June 2011 in Haematologica
Verified
Journal Article
Open access
PDF file
PCPatrice Chevallier
Patrice Chevallier
MLM. Labopin
M. Labopin
JCJ. Cornelissen
J. Cornelissen
GSG. Socie
G. Socie
VRV. Rocha
V. Rocha
OEOn Behalf Of The Alwp Of Ebmt
On Behalf Of The Alwp Of Ebmt
Myeloid sarcoma (MS), also known as granulocytic sarcoma or chloroma, is a rare extramedullary tumor composed of immature myeloid cells at different stages of differentiation which can involve any site of the body. Most cases of myeloid sarcoma will develop within the first year preceding the

14 September 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
ABAmandine Le Bourgeois
Amandine Le Bourgeois
MCMarianne Coste-Burel
Marianne Coste-Burel
TGThierry Guillaume
Thierry Guillaume
PPPierre Peterlin
Pierre Peterlin
AGAlice Garnier
Alice Garnier
PCPatrice Chevallier
Patrice Chevallier
COVID-19, which is due to infection with SARS-CoV-2, results in poor outcomes in patients with hematologic cancers (approximately 40% mortality rate).1,2 The efficacy of anti-SARS-CoV-2 mRNA vaccines has been successfully demonstrated in healthy populations3 and also has been reported in immunocompromised patients. Recently, we showed that a first injection of the BNT162b2 (Pfizer-BioNTech) vaccine induced an antibody response in 55% of 112 allogeneic hematopoietic stem cell transplant (HSCT) recipients.4 Here, we document the antibody response to a second dose of BNT162b2 vaccine in an extended cohort of 117 patients.

10 September 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RKRathana Kim
Rathana Kim
Yves ChalandonYves Chalandon
Yves Chalandon
PRPhilippe Rousselot
Philippe Rousselot
JCJean-Michel Cayuela
Jean-Michel Cayuela
FHFrançoise Huguet
Françoise Huguet
ECEmmanuelle Clappier
Emmanuelle Clappier
PURPOSE: BCR::ABL1 quantification is widely regarded as the standard for monitoring measurable residual disease (MRD) in Philadelphia chromosome–positive (Ph+) ALL. However, recent evidence of BCR::ABL1 multilineage involvement questions the significance of BCR::ABL1 MRD. We aimed to define the prognostic role of MRD as assessed by BCR::ABL1 or lymphoid-specific immunoglobulin/T-cell receptor ( IG/TR) gene markers. PATIENTS AND METHODS: We conducted BCR::ABL1 and IG/TR quantification after each treatment cycle in 264 patients treated in the GRAAPH-2014 trial, which used four cycles of reduced-intensity chemotherapy with nilotinib, followed by hematopoietic stem-cell transplantation (HSCT). RESULTS: Comparing BCR::ABL1 and IG/TR MRD revealed residual BCR::ABL1-positive non-ALL cells in 98 (43%) of 228 patients, defining multilineage Ph+ ALL. Despite poorer BCR::ABL1 responses, patients with multilineage Ph+ ALL had similar disease-free survival (DFS; hazard ratio [HR], 0.83 [95% CI, 0.49 to 1.41]; P = .50). Although BCR::ABL1 response failed to predict outcomes, IG/TR positivity (≥0.01%) was strongly associated with lower DFS (after cycle 2, HR, 2.49 [95% CI, 1.40 to 4.40]; P = .002; after cycle 4, HR, 4.13 [95% CI, 1.82 to 9.38]; P = .001). In multivariable analysis, both IG/TR positivity after cycle 2 and initial WBC count ≥30 × 109/L predicted poorer DFS, enabling to define a high-risk group having a 4-year DFS of 56.5% compared with 87.6% (HR, 3.72 [95% CI, 1.93 to 7.15]; P < .001). Moreover, allogeneic HSCT significantly improved DFS in the high-risk group (HR, 0.33 [95% CI, 0.18 to 0.60]; P < .001), whereas the standard-risk group had favorable outcomes regardless of allogeneic HSCT. CONCLUSION: Our findings challenge the significance of BCR::ABL1 monitoring in adult Ph+ ALL and demonstrate the prognostic role of IG/TR MRD. This study provides a framework for using MRD to guide treatment strategies in adults with Ph+ ALL.